Phasenprophylaxe bei bipolaren Störungen

• Literatur

• 1 Kupfer D. Long-term treatment of depression. J Clin Psychiatry 2009; 52: 28-34
• 2 Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552
• 3 Benazzi F. Prevalence and clinical correlates of residual depressive symptoms in bipolar II disorder. Psychother Psychosom 2001; 5: 232-238
• 4 Runge C, Grunze H. Annual costs of bipolar disorders in Germany. Nervenarzt 2004; 9: 896-903
• 5 Berghöfer A, Adli M, Baethge C et al. Phasenprophylaxe. In: Deutsche Gesellschaft für bipolare Störungen, Hrsg. Weißbuch Bipolare Störungen in Deutschland. Norderstedt: BoD GmbH; 2006: 207-282
• 6 Nolen WA, Knoppert-van der Klein EAM, Bouvy PF et al. Richtlijn bipolaire stoornissen. Amsterdam: Boom; 2001
• 7 Grunze H, Kasper S, Goodwin G et al. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004; 5: 120-135
• 8 DGBS e. V. und DGPPN e. V.. S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion 1.4. Im Internet: www.leitlinie-bipolar.de Stand: Mai 2012, letzte Anpassung September 2012
• 9 Bauer M, Grof P, Gyulai L et al. Using technology to improve longitudinal studies: self-reporting with ChronoRecord in bipolar disorder. Bipolar Disord 2004; 6: 67-74
• 10 Bauer MS, Mitchner L. What is a “mood stabilizer”? An evidence-based response. Am J Psychiatry 2004; 161: 3-18
• 11 Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 9: 1013-1024
• 12 Geddes JR, Goodwin GM, Rendell J et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 9712: 385-395
• 13 Weisler RH, Nolen WA, Neijber A et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011; 72: 1452-1464
• 14 Lewitzka U, Felber W, Bauer M et al. Die suizidprophylaktische Wirkung von Lithium – Übersicht über den aktuellen Stand der Forschung und deren Implikationen für die Therapie von affektiven Störungen. Nervenarzt 2013; 84: 294-306
• 15 Lohse MJ, Müller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Paffrath D, Hrsg. Arzneiverordnungs-Report 2010. Berlin: Springer-Verlag; 2010
• 16 Severus WE, Kleindienst N, Seemüller F et al. What is the optimal serum lithium level in the long-term treatment of bipolar disorder – a review?. Bipolar Disord 2008; 2: 231-237
• 17 Goodwin GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994; 164: 149-152
• 18 Berghöfer A, Bauer M, Müller-Oerlinghausen B. Antisuicidal effect of lithium as a criterion for the selection of appropriate long-term medication in bipolar patients. In: Kaschka WP, ed. Perspectives in affective disorders. Advanced biological psychiatry. 21. Basel: Karger; 2002: 137-145
• 19 Bauer M, Grof P, Müller-Oerlinghausen B eds. Lithium in neuropsychiatry. The comprehensive guide. London: Informa healthcare; 2006
• 20 Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 5: 481-489
• 21 McElroy SL, Bowden CL, Collins MA et al. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. J Affect Disord 2008; 107: 127-133
• 22 Calabrese JR, Suppes T, Bowden CL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapidcycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 11: 841-850
• 23 Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 4: 392-400
• 24 Licht RW, Nielsen JN, Gram LF et al. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010; 5: 483-493
• 25 Keck Jr PE, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 4: 626-637
• 26 Keck Jr PE, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480-1491
• 27 Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, doubleblind, controlled clinical trial. Am J Psychiatry 2005; 7: 1281-1290
• 28 Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 2: 247-256
• 29 Quiroz JA, Yatham LN, Palumbo JM et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 2: 156-162
• 30 Altamura AC, Salvadori D, Madaro D et al. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. J Affect Disord 2003; 1–3: 267-271
• 31 Bowden CL, Vieta E, Ice KS et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 2: 130-137
• 32 Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 4: 402-407
• 33 Colom F, Vieta E, Reinares M et al. Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. J Clin Psychiatry 2003; 9: 1101-1105
• 34 Castle D, White C, Chamberlain J et al. Group-based psychosocial intervention for bipolar disorder: randomized controlled trial. Br J Psychiatry 2010; 196: 383-388
• 35 Lam DH, Watkins ER, Hayward P et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003; 2: 145-152
• 36 Miklowitz DJ, Simoneau TL, George EL et al. Familyfocused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biol Psychiatry 2000; 6: 582-592
• 37 Frank E, Kupfer DJ, Thase ME et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005; 62: 996-1004
• 38 Gonzalez JM, Prihoda TJ. A case study of psychodynamic group psychotherapy for bipolar disorder. Am J Psychotherapy 2007; 61: 405-422
• 39 Fonagy P, Roth A, Higgitt A. Psychodynamic psychotherapies: evidence-based practice and clinical wisdom. Bull Menninger Clin 2005; 69: 1-58
• 40 Gonzalez-Isasi A, Echeburua E, Mosquera F et al. Long-term efficacy of a psychological intervention program for patients with refractory bipolar disorder: a pilot study. Psychiatry Res 2010; 2–3: 161-165
• 41 Miller IW, Solomon DA, Ryan CE et al. Does adjunctive family therapy enhance recovery from bipolar I mood episodes?. J Affect Disord 2004; 3: 431-436
• 42 Perry A, Tarrier N, Morriss R et al. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. Br Med J 1999; 318: 149-153
• 43 Daly JJ, Prudic J, Devanand DP et al. ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord 2001; 3: 95-104
• 44 Grunze H, Scharfstetter J. Elektrokonvulsionstherapie der manischen Episode im Rahmen einer bipolaren affektiven Störung. In: Baghai T, Frey R, Kasper S, Möller JJ, Hrsg. Klinische und wissenschaftliche Aspekte der Elektrokonvulsionstherapie. Wien: Springer; 2003
• 45 Golden RN, Gaynes BN, Ekstrom RD et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005; 4: 656-662
• 46 Tuunainen A, Kripke DF, Endo T. Light therapy for non-seasonal depression. Cochrane Database Systematic Review 2004; (02) CD004050. Review
• 47 DGPPN e. V.. S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen. Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/038020l_S3_Psychosoziale_Therapien_10-2012.pdf (Stand: 25.10.2012, gültig bis 25.10.2017)
• 48 Bauer M, Ströhle A. Behandlungsstrategien bei prophylaxeresistenten bipolaren Störungen. Nervenarzt 1999; 70: 587-599
• 49 Calabrese JR, Rapport DJ, Youngstrom EA et al. New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder. Eur Psychiatry 2005; 20: 92-95
• 50 Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord 2012; 14: 863-869
• 51 Baethge C, Baldessarini RJ, Mathiske-Schmidt K et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry 2005; 66: 174-182
• 52 Suppes T, Vieta E, Liu S et al. Trial 127 investigators. Maintenance treatment for patients with bipolar disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166: 476-488
• 53 Bauer M, Berghofer A, Bschor T et al. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacol 2002; 27: 620-628